Articles tagged with B Cell Receptors
Researchers at Stanford Medicine have devised a way to mine the immune system's internal database to diagnose diseases such as diabetes and COVID-19. The machine-learning based technique, called Mal-ID, uses B and T cell receptor sequences and structures to identify individuals with specific diseases.
CAR-T cell therapy, a regenerative immunotherapy, has shown promise in treating blood cancers but struggles with T-cell exhaustion. Researchers have discovered that overproduction of the IL-4 protein causes this exhaustion and used CRISPR gene-editing technology to remove it, improving CAR-T cell therapy outcomes.
Researchers from Osaka University found that Csk inhibits germinal center B cell signaling, decreasing reactive oxygen species production and promoting affinity maturation. This study reveals the crucial role of Csk tyrosine kinase in regulating B cell development.
A new method developed at Karolinska Institutet can identify unique immune cell receptors and their location in human tissue. This breakthrough could lead to the development of novel therapies for diseases such as cancer and autoimmune disorders, by pinpointing the specific immune cells responsible.
Researchers found a quantitative difference in B cell response following vaccination between young and older adults, with younger adults mounting a stronger clonal response and older adults having more activated B cells. This study provides insights into the age-related differences in B cell vaccine response and may lead to the develop...
Researchers developed a new method to assess immune responses to specific antigens after mRNA SARS-CoV-2 vaccine administration, using B cell receptor repertoire analysis. This approach enables evaluation of post-vaccination responses in immunocompromised patients with high antibody titers.
Researchers developed a novel vaccine against SARS-CoV-2 by selecting antigen variants with low binding affinity, resulting in higher neutralizing antibody concentrations. This design strategy may also improve vaccine efficacy for other coronaviruses and herpes viruses.
Scientists have elucidated the exact molecular structure of an IgM-type B cell receptor, revealing its asymmetrical complex with signaling subunits. The discovery provides insights into how the receptor interacts with other molecules and could lead to a better understanding of vaccine development and lymphoma formation.
Researchers discovered a nanomaterial that boosts antibody production while minimizing inflammation, opening up new possibilities for vaccine development. The 'micelle' scaffolds can be used to generate laboratory-scale quantities of therapeutic antibodies against real-world pathogens.
Researchers at the University of Southampton have identified a unique change in B cells that allows them to receive signals from molecules called lectins, enabling tumor growth. This discovery could pave the way for new treatments and early cancer detection methods.
Researchers at Max Delbrück Center found that B1-typical B-cell receptor can reprogram B2 cells into B1 cells, suggesting a new origin for B1 cells. This discovery provides clear evidence for the validity of the second hypothesis on the origin of B cells.
Scientists have sequenced a key part of the human immune system, discovering unexpected overlaps between adults and infants' antibody sequences. This finding could provide potential new targets for vaccines and treatments that work across populations.
Researchers found that in people living with HIV, a type of antibody called immunoglobulin G3 (IgG3) stops B cells from doing their normal job of fighting pathogens. This phenomenon appears to be one way the body tries to reduce immune-system hyperactivity caused by HIV.
Researchers at the University of Freiburg have identified Kidins220/ARMS as a crucial protein in B cell development and activation. The protein plays a key role in regulating the formation of antibodies and weakening the immune system if it is deficient.
Researchers have discovered a potential treatment for cancer of the immune system, targeting the Epstein Barr virus receptor EB12. The discovery was made by mapping the bio-antenna molecule and creating a blueprint of a tiny molecule that can bind to the B cell EB12 receptor, blocking its activation.
B-cell receptors form ordered oligomer complexes that only become active when binding partners disintegrate into subunits. This new model challenges the accepted scientific doctrine and may contribute to the development of new vaccination strategies and treatments for B-cell tumours.
Immunologist Roberta Pelanda and her team found that immature B cells require a positive signal from the B-cell receptor to mature and enter the spleen. Protein Erk helps deliver this signal, enabling B cells to escape the bone marrow and contribute to immune defense.
Researchers at NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases found that up to 10% of B cells retain faulty receptors, escaping correction. This discovery sheds light on the development of self-reactive B cells in autoimmune disease.